AVNS - Avanos Medical, Inc.
Sintx Technologies (NASDAQ: SINT - Get Free Report) and Avanos Medical (NYSE: AVNS - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability. Insider and Institutional Ownership 18.4% of Sintx Technologies
Bank of America Corp DE grew its position in shares of Avanos Medical, Inc. (NYSE: AVNS) by 30.2% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 110,978 shares of the company's stock after purchasing an additional 25,767 shares during the quarter.
BlackRock Inc. purchased a new position in Avanos Medical, Inc. (NYSE: AVNS) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 7,468,794 shares of the company's stock, valued at approximately $185,824,000. BlackRock Inc. owned 15.94% of Avanos Medical at the end of
NEW YORK--(BUSINESS WIRE)--Sterlington advises Avanos Medical management team on $1.27 billion acquisition.
ALPHARETTA, Ga., July 22, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) ("Avanos" or the "Company"), a leading medical technology company, today announced that its stockholders have voted to approve the pending acquisition of Avanos by affiliates of investment funds advised by American Industrial Partners ("AIP") at a special meeting of stockholders (the "Special Meeting") held earlier today.
NEW YORK, July 20, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600
ALPHARETTA, Ga. and NEW YORK, July 2, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) ("Avanos") and American Industrial Partners ("AIP") jointly announced the receipt of all required regulatory approvals to complete the pending acquisition of Avanos by affiliates of investment funds advised by AIP (the "Merger").
Are CRBG, EQH, AVNS Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propos
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avanos Medical, Inc. (NYSE: AVNS) to affiliates of American Industrial Partners. Under the terms of the proposed transaction, shareholders of Avanos will receive $25.00 in cash for each share of Avanos that they own. KSF is seeking to determine whether this consideration and the process that led to i.
AVNS' SNS momentum, Nexus Medical integration and AIP deal support growth, but tariff costs, margin pressure and PM&R weakness remain headwinds.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
$HAREHOLDER ALERT: The M&A Class Action Launches Legal Inquiry for the Merger--AFBI, QXO, BLD, and AVNS PR Newswire
AVNS, BKR and CAG have been added to the Zacks Rank #5 (Strong Sell) List on May 15th, 2026.
Explore Avanos Medical's (AVNS) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Avanos Medical tops Q1 revenue estimates on strong SNS growth, but margin pressure and PM&R weakness weigh on earnings and profitability.
BALA CYNWYD, Pa. , May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith. com) or Marc Ackerman (mackerman@brodskysmith. com) at 855-576-4847.